KERX - Keryx Biopharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue31,98313,68010,825
Cost of Revenue40,6896,644495
Gross Profit-8,7067,03610,330
Operating Expenses
Research Development29,50436,69451,502
Selling General and Administrative84,55381,41070,057
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-122,763-111,068-111,229
Income from Continuing Operations
Total Other Income/Expenses Net-38,252-11,987411
Earnings Before Interest and Taxes-161,015-123,055-110,818
Interest Expense---
Income Before Tax-161,015-123,055-110,818
Income Tax Expense8090700
Minority Interest---
Net Income From Continuing Ops-161,095-123,145-111,518
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-161,095-123,145-111,518
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-161,095-123,145-111,518